Faster Results for Experimental Rx in Chronic Migraine

This article originally appeared here.
Share this content:
Faster Results for Experimental Rx in Chronic Migraine
Faster Results for Experimental Rx in Chronic Migraine

THURSDAY, June 9, 2016 (HealthDay News) -- An experimental drug -- TEV-48125 -- brings fast relief to patients with debilitating chronic migraines, according to a new study published online June 8 in Neurology.

The new study findings come from a reanalysis of an early trial of TEV-48125. In that study, 261 patients with chronic migraine were randomly assigned to take monthly injections of the drug -- at a higher (900 mg) or lower (675/225 mg) dose -- or a placebo, for three months.

The original study found that patients on TEV-48125 saw a drop in the number of hours they had headache pain each month. On average, the whole study group had 162 headache hours a month at the start of the study. Three months later, that had dropped by 60 to 67 hours, on average, among patients on the new drug. The new study found that the effects started as early as three days after the higher-dose injection, and seven days after the lower dose.

"To my knowledge, that's the fastest separation ever demonstrated in chronic migraine," lead researcher Marcelo Bigal, M.D., of Teva Pharmaceuticals, the company developing TEV-48125, told HealthDay. So far, Green said, there have been "no significant safety signals" with the drug. In the original study, the most common side effects were pain at the injection site and skin irritation.

Abstract
Full Text

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

900 Steps Tied to Functional Decline in Hospitalized Seniors

<900 Steps Tied to Functional Decline in Hospitalized ...

Walking <900 steps/day linked to hospitalization-associated functional decline

Thromboprophylaxis Not Effective After Knee Arthroplasty, Casting

Thromboprophylaxis Not Effective After Knee Arthroplasty, Casting

Does not prevent venous thromboembolism after knee arthroplasty, casting of lower leg

ASH: Lower Rate of Sickle Cell Pain Crises With Crizanlizumab

ASH: Lower Rate of Sickle Cell Pain Crises ...

Lower rate of crises per year; longer median time to first, second crises with high-dose therapy

is free, fast, and customized just for you!

Already a member?

Sign In Now »